Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Immunobiological aspects of vaccines in pregnancy: Maternal perspective

Helen Y. Chu\textsuperscript{a}, Arnaud Marchant\textsuperscript{b}

\textsuperscript{a}Departments of Medicine and Epidemiology, University of Washington, Seattle, WA, United States, \textsuperscript{b}Institute for Medical Immunology, Université libre de Bruxelles, Brussels, Belgium

Introduction

Pregnancy is associated with important changes in the maternal immune system that have profound consequences for the fetus and the newborn infant. Tolerance of the fetus and successful pregnancy require a highly regulated immunological environment at the materno-fetal interface \cite{1}. Maternal immune components are transferred across the placenta and in breastmilk that provide protection against pathogens in early life and contribute to immune development. Although pregnancy cannot be considered a state of immunodeficiency, infections with some pathogens cause more severe diseases in pregnant as compared to non-pregnant women. Vaccination during pregnancy has the potential to provide protection against pathogens affecting the mother and the newborn infant \cite{2,3}. However, the efficacy of this approach can be limited by diseases affecting maternal immune responses and transfer of maternal immune components to the offspring. Recognizing that the health of the mother during pregnancy is essential to the health of the newborn infant, maternal vaccination has a great potential to reduce morbidity and mortality in mothers and children.
Susceptibility to infectious diseases in pregnancy

Infections with some pathogens, including influenza virus, varicella zoster, hepatitis E, listeria, and malaria, cause more severe diseases in pregnant as compared to non-pregnant women. The mechanisms underlying this increased susceptibility have not been fully defined. Pregnancy-induced changes in the maternal immune system may play a role. On the other hand, pregnant women also have hormonal and physiologic changes including increasing levels of estradiol and progesterone and decreased pulmonary reserve and increased cardiac output that may contribute to reduced pathogen control and more severe clinical symptoms. As discussed below, emerging evidence suggest a central role for pathogen-specific mechanisms rather than processes common to multiple pathogens (Fig. 1). Understanding these mechanisms is critical for the development of interventions protecting pregnant women and their offspring.

Influenza and other respiratory viruses

Pregnant women have higher morbidity and, in some studies, mortality due to influenza infection as compared to non-pregnant adults [4]. In the 1918 pandemic, 27% mortality was observed in pregnant women [5,6].

**FIG. 1** Pathogens causing severe infections in pregnant women. Several pathogens cause more severe diseases in pregnant as compared to non-pregnant women. The pathogenesis underlying this increased susceptibility remains incompletely understood. Studies indicate that they involve pathogen-specific mechanisms rather than a global state of immunodeficiency (arrows). Severe symptoms can compromise the survival of the mother and of the unborn fetus.
In the 2009 influenza A/H1N1 pandemic, pregnant women with influenza particularly towards the end of pregnancy in the third trimester had increased disease severity, higher rates of secondary bacterial pneumonia, and increased risk of both hospitalization and admission to the intensive care unit as compared to non-pregnant adults [7]. Higher rates of stillbirth, miscarriage, and preterm birth were additionally observed with A/H1N1 pandemic influenza infection during pregnancy [8]. Epidemiologic data do not clearly support an increased risk of acquisition of infection; rather the risk is in progression to severe disease once infected [9]. However, a recent systematic review emphasized the relatively low quality of available information on the incidence rate of severe influenza in pregnant women [10]. The mechanisms underlying severe influenza in pregnancy remain unclear and could involve both anatomic and physiologic changes increasing the risk of respiratory failure, reduced immune control and increased inflammatory responses [9]. Enhanced natural killer (NK) cell and T cell responses to influenza infection were observed in pregnant as compared to non-pregnant women, suggesting that suppression of cell-mediated immune responses is unlikely to be a major contributor to disease severity [11]. Mouse studies suggest a role for impaired migration of anti-viral CD8 T lymphocytes to the lungs [12]. Increased proinflammatory responses of monocytes and dendritic cells to in vitro influenza infection were observed in pregnant as compared to non-pregnant women, suggesting a role for immunopathologic responses [13]. Influenza vaccine is safe, immunogenic and efficacious in pregnancy, as has been demonstrated in several randomized clinical trials [14–17].

Few studies have evaluated the role of respiratory viruses other than influenza during pregnancy [18]. However, recently, two maternal influenza immunization trials have conducted secondary analyses of respiratory illness data during pregnancy to describe the incidence of maternal respiratory disease due to respiratory syncytial virus (RSV) during pregnancy [14,16]. In Nepal, where women with a fever and respiratory symptoms had a nasal swab collected, RSV prevalence was low at 0.2%, with an incidence of 3.9/1000 person-years overall [19]. In South Africa, RSV prevalence based on the presence of respiratory symptoms was much higher at 2%, or an incidence of 14.4–48.0 cases per 1000 person-years overall [20]. Rhinovirus, coronavirus, parainfluenza viruses 1–4, and human metapneumovirus have also recently been detected in cases of respiratory viral infections in pregnant women [21,22]. Rhinovirus is described as a cause of influenza-like illness in several studies in pregnant women, and Middle Eastern Respiratory Syndrome and Severe Acute Respiratory Syndrome coronaviruses have been shown in case reports to be associated with severe disease in pregnant women [23,24]. Other respiratory viruses were commonly detected in Nepal in women with fever and respiratory symptoms, with the most common being rhinovirus [22]. Health care-seeking
was also common, ranging from 0% to 33% depending on the viral etiology. In a region of the world with limited access to medical care, this was a notable finding. Additionally, rhinovirus and human metapneumovirus infections with fever and respiratory symptoms during pregnancy both were found to be associated with increased risk of fetal growth restriction, manifested as low birth weight or small-for-gestational-age births [21]. Overall, these studies demonstrate that respiratory viral infections during pregnancy may adversely affect maternal and fetal outcomes.

### Varicella zoster virus

Pregnant women may be at increased risk of progression of varicella to pneumonitis, particularly in the third trimester, with a mortality rate of 44% [25]. However, much of these data are based on case reports [26]. To our knowledge, no prospective studies have been conducted comparing the risk of varicella pneumonitis in pregnant versus non-pregnant women. Varicella infection during pregnancy is associated with disseminated disease and with adverse outcomes in the fetus, including congenital varicella, characterized by limb hypoplasia, optic nerve atrophy, microcephaly, seizures, cutaneous lesions [27]. Varicella zoster vaccination is now routine as part of the childhood immunization series in some countries; prior to vaccination, the majority of individuals were exposed during childhood with acquisition of immunity prior to pregnancy. Treatment for varicella infection in pregnancy is with acyclovir; use of live vaccines are contraindicated during pregnancy due to potential risk of fetal transmission.

### Hepatitis E

Hepatitis E is acquired via fecal-oral transmission, and is a pathogen often associated with limited access to running water and basic sanitation. In a field study of viral hepatitis in pregnant versus non-pregnant adults in the 1980s, incidence of non-A non-B hepatitis was increased in pregnant women (17.3% vs. 2.1%, respectively). In this study, fulminant hepatitis developed in 22% of pregnant women as compared to no cases of fulminant hepatitis in non-pregnant women [28]. The incidence is increased in the second and third trimester as compared to the first trimester. Mortality has been estimated at 25–30% in pregnant women [29]. The mechanisms underlying the increased susceptibility of pregnant women to hepatitis E infection and not to other hepatitis viruses is not clear. A role for estradiol promoting hepatitis E virus replication has been suggested [30]. Thus far, no treatment is available other than supportive care and no vaccine is available.
Listeria monocytogenes

Listeria is a bacterial infection that is associated with consumption of raw meats or vegetables, or drinking unpasteurized milk. Risk is higher in Hispanic populations, the elderly, those with malignancy, as well as pregnant women. Pregnant women are considered a high-risk group for development of disseminated disease, commonly manifested as bactereemia or meningoencephalitis [31]. Listeria has a predilection for invasion of the placenta, and is associated with adverse pregnancy outcomes, including miscarriage and stillbirth [32,33]. In a study in Britain between 1967 and 1985, 34% cases of listeria were during pregnancy, with an association with intrauterine fetal death and neonatal infection [32]. Although the pathogenesis of severe listeriosis during pregnancy is not well understood, it may involve establishment of an infectious reservoir at the level of placenta and uncontrolled dissemination to maternal organs [34].

Malaria (Plasmodium falciparum)

In malaria-endemic regions, pregnant women are estimated to have three-times increased risk of severe malaria as compared to non-pregnant adults [35]. Plasmodium falciparum has a tropism for the placenta and increases the risk of low birth weight and preterm birth. Women who are in their first pregnancy, as well as those who are younger, are at higher risk than multigravida women. This reflects acquisition of antibodies against placenta-adhesive parasites during consecutive pregnancies [36]. Chemoprevention against malaria is recommended during the second and third trimesters in endemic areas [37]. Therapy with artemesin was thought to be toxic to fetal development. However, the use of artemisin derivatives has now been demonstrated to be safe and effective in treatment of pregnant women early in pregnancy [38]. Maternal immunity transferred across the placenta provides protection against severe malaria in infants [39].

Other pathogens transmitted from the mother to the fetus and newborn infant

Several pathogens that are often asymptomatic in pregnant women cause a serious threat to the fetus and the newborn infant. These pathogens are therefore considered as targets for immunization of children, teenagers or women of childbearing age. This approach has been successfully applied to the prevention of congenital rubella syndrome in high income countries and, increasingly, in low and middle income countries [40].

Herpes simplex virus

Primary genital herpes infection during pregnancy may be associated with fulminant hepatitis and disseminated disease, as compared to
primary herpes simplex virus (HSV) infections in non-pregnant adults, though the data for this is not conclusive [41]. The risk of neonatal herpes is substantially higher in women with primary disease with both HSV1 and HSV2 during pregnancy, rather than those who have disease reactivation during pregnancy [41]. Because many women with genital herpes are asymptomatic or have mild symptoms, diagnosis and treatment may be challenging, requiring the use of serology for evidence of preexisting antibody to HSV1 and HSV2. The target population for vaccination against herpes is likely prior to onset of sexual activity; however, currently no licensed vaccine exists. Multiple vaccine candidates have not shown efficacy in prevention of primary infection; however, multiple new vaccines are under development [42,43]. Mouse studies recently demonstrated the maternal HSV immunization confers protection against neonatal mortality and behavioral morbidity [44]. Neonatal herpes is associated with a 60% mortality rate if untreated. The route of acquisition is most commonly through exposure in the genital tract during vaginal delivery; therefore caesarean section is indicated in women with known active genital herpes at the time of delivery.

**Cytomegalovirus**

Women with cytomegalovirus (CMV) infection during pregnancy generally exhibit a range of disease severity similar to non-pregnant adults, ranging from asymptomatic infection to a mononucleosis-like syndrome with fevers, rash, and lymphadenopathy. Risk factors for primary CMV infection during pregnancy include exposure to infected young children excreting the virus for prolonged periods of time. Clinical manifestations of CMV infection in the fetus include sensorineural hearing loss, chorioretinitis, intrauterine growth restriction, preterm birth, hepatosplenomegaly, microcephaly, and fulminant disease [45]. Primary infection early in pregnancy is associated with a higher risk of transmission to the fetus, with estimates of 32% with primary infection as compared to 1% following recurrent infection. Recurrent infections include both reactivation of latent virus and acquisition of a new strain of CMV [46]. Similar to herpes simplex, the target of CMV vaccination would be young children or adolescents prior to pregnancy. A number of CMV vaccine candidates are currently in development [47,48], though none are licensed.

**Zika virus**

Zika virus is a re-emergent pathogen that has particular implications for pregnant women. Symptoms of Zika virus infection during pregnancy include maculopapular rash, arthralgia, conjunctivitis and low grade fever [49]. Like CMV and rubella, infection with zika earlier in pregnancy is associated with increased risk of congenital birth defects, including microcephaly and intrauterine growth retardation. Pregnant women are likely
to have prolonged viremia due to zika virus, as compared to non-pregnant adults, and infection during pregnancy is associated with increased risk of congenital birth defects [50]. The United States Centers for Disease Control guidelines recommend that laboratory studies for zika virus by molecular testing or serology are indicated in women with clinical suspicion of zika virus infection, with history of exposure via travel or residence in a region where mosquito-borne transmission of zika is documented, or unprotected sexual contact with a partner who has traveled to these areas [51]. Viral infection during pregnancy is thought to lead to placental infection, and transmission to fetal neuronal cells, leading to cell injury and death. The risks of congenital infection appear to be high in women with documented zika virus infection during pregnancy; in a prospective study in Brazil, 42% of infants born to women with diagnosed infection during pregnancy had abnormal clinical or brain imaging findings [52]. These occurred in 55%, 52% and 29% of pregnancies where infection occurred in the first, second or third trimester of pregnancy, respectively. No specific treatment or vaccine is currently available, with current recommendations including avoidance of travel to endemic areas, use of barrier contraception to protect against sexual transmission, and use of standard precautions to prevent mosquito bites.

Innate and adaptive immune responses in pregnancy

The fetus expresses paternal antigens and is therefore a semi-allogeneic graft for the pregnant women. Multiple redundant mechanisms have been selected to promote immunological tolerance of the fetus and to allow successful pregnancy. At the materno-fetal interface, the placenta is a highly immunoregulated environment containing large numbers of innate and adaptive immune cells, including NK cells, T lymphocytes and myeloid cells, actively suppressing fetal tissue rejection [1].

Pregnancy is also associated with significant changes in the number and function of immune cells at the systemic level. Recent analyses of immune cell responsiveness to activation signals indicate dynamic and coordinated changes from the first to the third trimester of pregnancy, suggesting an “immune clock” regulating immune functions in pregnant women [53]. Relevant to antibody responses to vaccination are B cells, follicular helper T cells and antigen-presenting cells. Studies have examined the influence of pregnancy on B cells and antigen-presenting cells but its impact on follicular helper T cells remains to be assessed. Most studies showed that pregnancy is associated with decreased B cell numbers in peripheral blood [54–59]. Studies in mice indicated that estrogens produced during pregnancy reduce B cell lymphopoiesis [60]. Studies of the influence of hormones on B cell functions indicate that pregnancy may impact the production of

I. Concepts of maternal immunization
immunoglobulins. Estrogen increases the production of immunoglobulin G (IgG) by human B cells and prolactin decreases the threshold of B cell activation \[61,62\]. However, total serum IgG levels are lower in pregnant than in non-pregnant women in both low and high income country settings, a phenomenon that probably involves hemodilution \[63,64\]. On the other hand, populations living in low income countries, including pregnant women, commonly have elevated serum levels of IgG, probably as a result of high and chronic exposure to microbial antigens, such as malaria \[63,65,66\]. A recent study indicated that estrogen stimulates the production of natural antibodies against bacterial oligosaccharides \[67\]. These antibodies were transferred from the mother to the offspring and protected mice against entheropathogenic *Escherichia coli* infection. Together, these studies indicate that sex hormones and pregnancy modulate the number of B lymphocytes and their production of immunoglobulins.

Significant changes in the quality of IgG are also observed during pregnancy. IgG are glycoproteins carrying N-glycans at both the Fc and Fab segments \[68,69\]. The composition of the N-glycans influences the three-dimensional structure of the Fc segment of IgG and the interaction of IgG with Fcγ receptors and complement. In total, 36 glycovariants can be attached to the Fc segment of IgG. In combination with the four IgG subclasses, this diversity offers the potential to fine tune IgG effector functions \[69\]. Pregnancy is associated with increased galactosylation and sialylation and with decreased fucosylation of total IgG Fc \[70\]. These changes have the potential to modulate the capacity of IgG to activate NK cells and complement and to reduce their inflammatory properties \[71,72\]. The clinical relevance of these modifications is supported by the association of IgG galactosylation and remission of rheumatoid arthritis in pregnant women \[73\]. Mouse studies suggest that estrogen upregulates the expression of the activation-induced deaminase, the enzyme that initiates class switch recombination and somatic hypermutation of immunoglobulins \[74\]. The impact of estrogen and pregnancy on the subclass and the avidity of antigen-specific IgG remains poorly characterized.

Changes in antigen-presenting cells are also observed in pregnant women. The absolute number of myeloid dendritic cells (mDC) was shown to increase in the first trimester and decrease as pregnancy progressed to reach similar counts in the third trimester as in non-pregnant women \[75,76\]. In contrast, the numbers of plasmacytoid (p)DCs were shown to be reduced during the third trimester of pregnancy, resulting in a higher mDC: pDC ratio \[75,77,78\]. Pregnancy is also associated with changes in Toll-like receptor (TLR) expression by circulating DC subsets. Increased expression of TLR-1 by mDC and of TLR-7 and TLR-9 by pDC was detected \[79\]. The role of these changes in the modulation of immune responses during pregnancy have not yet been explored.
Potentially relevant to the modulation of immune responses during pregnancy are the changes in the composition of the maternal microbiome. The composition and the diversity of the microbiome is influenced by pregnancy at several body sites, including the oral cavity, the gut and the genital tract [80]. Mouse studies suggest that changes in the gut microbiome may promote inflammatory responses and participate in the physiological changes in metabolism associated with pregnancy [81].

Effect of pregnancy on vaccine responses

The impact of pregnancy and sex hormones on B cells, antigen-presenting cells and microbiome suggests a possible influence on the magnitude and quality of antibody responses to vaccines. This notion is supported by the observation that the magnitude of antibody responses to vaccines is often higher in women than in men [82]. Overall, vaccines are immunogenic in pregnant women [2,3]. However, relatively few controlled studies have compared vaccine responses in pregnant and non-pregnant women. Available data come from studies of influenza or pertussis immunization and are not consistent across studies. Four studies described similar antibody responses to seasonal influenza vaccines in pregnant and non-pregnant women [83–86]. On the other hand, other studies reported lower responses in pregnant women following immunization with seasonal and pandemic influenza vaccines [87–89]. Whether the gestational stage of pregnancy affects responses to vaccines is uncertain. Similar antibody responses to seasonal and pandemic influenza vaccination were observed throughout pregnancy in two studies whereas a recent study reported a decline in the antibody response to seasonal influenza immunization and a relative increase in the proportion of the IgG4 subclass [84,89,90]. Fewer studies have examined the impact of pregnancy on the antibody response to pertussis immunization. Two studies reported similar antibody responses to pertussis immunization in pregnant and non-pregnant women [91,92]. However, one of the two studies reported lower T cell responses to pertussis antigens in pregnant as compared to non-pregnant women [92]. A recent study involving a larger sample size observed lower antibody responses to pertussis toxin and filamentous hemagglutinin in pregnant as compared to non-pregnant women [93]. Factors responsible for the discordant results obtained in different studies are unclear but are possibly attributable to the relatively small size of the population included in most studies and to differences in tested vaccines and in participant characteristics, including pre-vaccination antibody titers that are an important determinant of vaccine responses [94]. The persistence of antibodies following maternal immunization will influence the optimal timing of immunization and the requirement to repeat immunization during consecutive
Pertussis antibodies decay rapidly supporting the need to immunize during each pregnancy, as is recommended in an increasing number of high income countries [95,96]. Antibody decay following immunization with adjuvanted pandemic influenza vaccine was similar in pregnant and non-pregnant women [88]. The impact of pregnancy on the quality of the antibody response to vaccines remains largely uncharacterized. A study showed that the avidity of cord blood antibodies is higher following pertussis immunization at 27–30 weeks as compared to after 31 weeks of gestation, a difference that is likely related to the time needed to increase antibody avidity following booster immunization rather than to an impact of gestational stage [97]. The impact of pregnancy on the glycosylation profile and on the functional properties of vaccine-induced antibodies remains to be investigated.

The evidence that pregnancy induces changes in circulating antigen-presenting cells and in the composition of the microbiome suggests that innate immune responses and inflammatory reactions to vaccines may also be influenced. In one study, pregnant women given seasonal influenza vaccine had increased plasma levels of inflammatory cytokines during the first days after vaccination but these responses were similar to those in non-pregnant women [85]. In a recent study, pregnant women were more likely to report moderate and severe pain at the injection site following pertussis immunization as compared to non-pregnant women but the occurrence of other local and systemic reactions following vaccination was similar in both groups [93].

With the exception of maternal human immunodeficiency virus (HIV) infection, the impact of maternal diseases on responses to vaccination remains largely uncharacterized. In South Africa, maternal HIV infection was associated with lower seroconversion rates after seasonal influenza vaccination but vaccine efficacy was comparable to that observed in HIV-uninfected pregnant women [16]. HIV infection was also associated with lower immunogenicity of a candidate glycoconjugate Group B streptococcus vaccine in pregnant women [98]. Immunogenicity of pandemic A/H1N1 influenza vaccination in HIV-infected pregnant women correlated positively with pre-vaccination immunity and negatively with HIV replication [99]. Hypergammaglobulinemia is commonly observed in pregnant women living in low income countries but its impact on antibody responses to vaccines has not been characterized.

**Transfer of maternal antibodies to the newborn infant**

Transfer of maternal antibodies to the fetus and newborn infant across the placenta and breastmilk provides protection against infectious pathogens to which the mother has been exposed. In addition, recent studies indicate that
maternal antibodies also contribute to infant gut homeostasis by shielding commensal bacteria, impacting the development of the gut immune system and to the prevention of allergic responses in early life [100–102].

Of the immunoglobulins in the maternal circulation, only IgG is transferred transplacentally [68,103]. Studies suggest that maternal IgE could be transported complexed with IgG [104]. Transfer of antibodies is an active process beginning at the end of the first trimester of pregnancy. By the end of the second trimester, transplacental antibody ratios are about 50% and are greater than 100% at birth in full-term newborns [105,106]. As a result, infants born prematurely have lower levels of maternal antibodies, increasing risk for vaccine-preventable diseases [107]. IgG subclass is an important determinant of transfer across the placenta. Antibody transfer ratio is highest for IgG1 and lowest for IgG2 [68,103,106]. Transfer of IgG is also influenced by their antigen specificity [107]. Transfer of polysaccharide antigen-specific IgG is lower than protein antigen-specific IgG, a difference that is likely related to the lower transfer of IgG2. However, there is considerable variation in transfer ratios among protein antigen-specific and polysaccharide antigen-specific antibodies, suggesting that other factors than IgG subclass may play a role. Among them, IgG glycosylation could be involved. Indeed, IgG of different antigen-specificities have different glycosylation profiles and some studies suggest selective transfer of IgG expressing specific glycovariants [108,109].

Transport of maternal IgG to the fetus involves crossing several placental layers, including syncytiotrophoblasts, the fetal endothelium and the stroma that separates the two cell layers [103,106]. The neonatal Fc receptor (FcRn) is the main receptor transporting maternal IgG across syncytiotrophoblasts. Following endocytosis from the maternal circulation, the Fc segment of IgG binds the FcRn at acidic pH. The endosome is then transported to the basal surface of the syncytiotrophoblast where IgG dissociate from the FcRn at physiologic pH. As the FcRn is not expressed by fetal endothelial cells, other receptors have to participate in the transport of IgG to the fetal circulation. Studies suggest that the FcγRIIb2 expressed by fetal endothelial cells could be involved but its role in maternal antibody transfer is still debated [110,111]. A better understanding of the molecular and cellular basis of maternal antibody transfer across the placenta would help designing vaccines inducing antibodies with optimal transferability to the fetus.

Timing of maternal immunization

For maternal vaccine delivery, the decision of when to vaccinate during pregnancy needs to consider several variables, including limited antenatal care for many women in developing countries leading to a need for
an increased vaccination window, the need to protect preterm infants who would not benefit from vaccination late in pregnancy, and the optimal timing for antibody affinity maturation and transplacental transfer. In the United States, current recommendations are to administer pertussis-containing vaccines during pregnancy from 27 to 36 weeks gestation, which then requires about 2 weeks to have a serologic response, followed by transplacental antibody transfer [112]. This recommendation leads to an at-risk group of infants who are born earlier than 30 weeks gestation, who are also at highest risk for severe disease due to pertussis. It also potentially limits protection of infants born closer to term when maternal immunization is performed shortly before delivery. A recent prospective observational study examined concentrations of anti-pertussis toxin and anti-filamentous hemagglutinin IgG in newborns of women who received second versus third trimester vaccination [113]. Overall, higher concentrations of cord blood antibodies to both pertussis toxin and filamentous hemagglutinin were detected following second trimester versus third trimester vaccination. Although maternal vaccine responses were not measured, the data were interpreted as the consequence of the longer duration of antibody transfer following vaccination during the second trimester of pregnancy. Immunization against pertussis is recommended from the second trimester of pregnancy in several countries, including the United Kingdom and Belgium, but currently not in the United States [112,114].

For influenza vaccination in pregnancy, the recommendation in industrialized countries is to vaccinate any time during pregnancy during influenza season. There are many countries where influenza circulates many months during the year, including subtropical Asia and sub-Saharan Africa. In these settings, influenza vaccination may be considered as a year-round vaccination strategy and has been shown to be efficacious in a randomized clinical trial of maternal influenza vaccination in Nepal [14]. In this study, women were additionally randomized to second or third trimester vaccination to evaluate the effect on infant influenza vaccine efficacy [115]. The results from this study showed that there was no significant difference in influenza vaccine efficacy by second or third trimester vaccination, and there was a nonsignificant trend towards improved birth weight with earlier vaccination. Cord blood anti-hemagglutination inhibition titers against A/H3N2, A/H1N1 and B antigens was not different between the two groups, though the numbers of samples tested were small. Therefore, available data regarding pertussis and influenza vaccine timing in pregnancy suggest that earlier vaccination is not associated with decreased efficacy against disease in mothers and infants. As vaccination from the second trimester of pregnancy offers the advantage to protect preterm infants and to increase the potential window for vaccination in settings where it may be challenging to access pregnant women, further studies should be conducted to consolidate these observations in different populations. Limited information is available

I. Concepts of maternal immunization
regarding the impact of timing of vaccination during pregnancy for other vaccines. The principle that optimal transfer of maternal antibodies requires sufficient time between maternal immunization and delivery is likely to apply. In a study of *Haemophilus influenzae* type B conjugate vaccine, transmission of antibodies was greatest in mothers vaccinated more than 4 weeks before delivery [116].

**Impact of chronic maternal infections on antibody transfer**

Chronic maternal infections, such as HIV and malaria, reduce the transfer of maternal IgG [117–120]. Studies conducted across different populations reported an association between reduced transfer of maternal IgG and placental malaria [117,121–124]. Trophozoites cause direct invasion of the placenta and could thereby alter IgG transfer. However, a recent study in Papua New Guinea indicated that this decreased transfer may not be directly related to placental malaria but rather due to hypergammaglobulinemia [125]. Hypergammaglobulinemia results from chronic inflammation and polyclonal B cell activation. It is generally considered that hypergammaglobulinemia impairs maternal antibody transfer by saturating the FcRn [106]. However, studies reported a variable impact of maternal hypergammaglobulinemia on transplacental transfer according to IgG subclass and antigen-specificity, suggesting that other factors involving placental receptors and cells or biophysical characteristics of IgG may be involved [117,121]. Little is know regarding the impact of hypergammaglobulinemia on transfer of IgG induced by vaccination during pregnancy.

Studies from low and high income countries reported decreased transfer of maternal IgG in children born to HIV-infected mothers across multiple vaccine and pathogen-specific antigens [119,126,127]. This is particularly significant given the increased infectious morbidity and mortality observed in HIV-exposed uninfected as compared to HIV-unexposed infants [120,128]. This notion is supported by a recent study conducted in Belgium, showing an association between reduced transfer of maternal antibodies, as well as immune activation in the newborn, and risk of hospitalization for infection during the first months of life in HIV-exposed uninfected infants [127]. Few studies have examined the impact of maternal HIV infection on the transfer of antibodies induced by vaccination during pregnancy. Following pandemic A/H1N1 influenza vaccination of HIV-infected pregnant women, cord blood antibody levels were higher than maternal antibody levels in some studies and lower in others [129]. This variability could be related to differences in the activity of maternal HIV infection across studies. Indeed, higher transfer ratios of maternal antibodies were observed in mothers who initiated anti-retroviral therapy before as
compared to during pregnancy [127]. Immunization of HIV-infected pregnant women is an important strategy to protect their vulnerable newborn infants but its efficacy can be limited by reduced vaccine immunogenicity and reduced transfer of maternal antibodies. The impact of HIV infection on the quality of maternal antibodies has not been explored. A better understanding of the impact of HIV in maternal immunity and its transfer to the newborn should help the design of optimal vaccination strategies.

Maternal antibody transfer through breastmilk

Breastfeeding is associated with improvement in a multitude of infant outcomes, particularly in low and middle income countries [130]. Exclusive breastfeeding is recommended by multiple professional groups for the first 6 months of life. Specifically, in relation to infectious risk, breastmilk decreases risk of sepsis and necrotizing enterocolitis in preterm infants, and is associated with decreased risk of respiratory viral infections, acute otitis media, and gastroenteritis [131]. Breastmilk contains secretory IgA and IgG. Other components of breastmilk include lactoferrin, lysozyme, white blood cells (predominantly neutrophils and macrophages), hormones, growth factors, and cytokines which could contribute to antiviral and antibacterial properties [3]. The synthesis of IgA is via plasma cells in the enteromammary and bronchomammary immune system. After exposure to antigens, maternal plasma cells synthesize secretory IgA antibody in the mammary gland and secrete this into milk. The polymeric Ig receptor (pIgR) transports secretory IgA and IgM into breastmilk [132]. Secretory IgA represents the major immunoglobulin in breastmilk, followed by secretory IgM and then IgG. In humans, ingested breastmilk antibodies do not enter the neonatal circulation, but secretory antibodies may prevent microbial colonization and invasion by coating mucosal surfaces [100]. Studies have shown that secretory IgA in colostrum can prevent HIV transcytosis across epithelium by direct neutralization [133]. Breastmilk IgG has also been shown to protect against HIV infection through antibody-dependent cytotoxicity [134]. A correlation between breastmilk IgG against respiratory syncytial virus with protection against acute respiratory infection has recently been reported [135]. Although the role of breastmilk antibodies in protection against disease is not well-studied, pathogen-specific IgA and IgG are induced in breastmilk by maternal immunization and could contribute to protection [3,136,137].

Conclusion

Immunization during pregnancy is an efficient strategy to protect both the mother and the newborn infant against infectious pathogens. As the
momentum for maternal immunization is growing, we have an opportunity to gain fundamental insights in the determinants of maternal immunity against pathogens and of its transfer to the newborn infant. Pregnancy is associated with many dynamic changes in maternal immune cells and molecules that are critical for tolerance of the fetus. These changes could have also been selected to modulate maternal immune components that are transferred to the newborn infant and thereby provide optimal protection against infectious pathogens after birth. Pregnancy modifies the glycosylation profile of maternal IgG and could also influence the production of individual IgG subclasses. Transfer of maternal IgG through the placenta, and potentially through breastmilk, could select antibodies with optimal biophysical and functional profiles. Unraveling these fundamental processes and identifying determinants of the magnitude and quality of vaccine responses in pregnant women offer the potential to optimize maternal immunization strategies. Most of the burden of infectious diseases affecting young infants is in low income countries where prevalence of maternal diseases, including chronic infections, is also highest. A more systematic evaluation and a better understanding of the impact of maternal diseases on vaccine-induced immunity and its transfer to the newborn are required to achieve the broadest impact of maternal immunization worldwide.

References

[1] Arck PC, Hecher K. Fetomaternal immune cross-talk and its consequences for maternal and offspring’s health. Nat Med 2013;19(5):548–56.
[2] Edwards KM. Maternal immunisation in pregnancy to protect newborn infants. Arch Dis Child 2019;104(4):316–9. https://doi.org/10.1136/archdischild-2017-313530. PMID: 29909381.
[3] Marchant A, Sadarangani M, Garand M, Dauby N, Verhasselt V, Pereira L, et al. Maternal immunisation: collaborating with mother nature. Lancet Infect Dis 2017;17(7):e197–208.
[4] Ortiz JR, Englund JA, Neuzil KM. Influenza vaccine for pregnant women in resource-constrained countries: a review of the evidence to inform policy decisions. Vaccine 2011;29(27):4439–52.
[5] Rasmussen SA, Jamieson DJ, Bressee JS. Pandemic influenza and pregnant women. Emerg Infect Dis 2008;14(1):95–100.
[6] Van Kerkhove MD, Vandemaele KAH, Shinde V, Jaramillo-Gutierrez G, Koukounari A, Donnelly CA, et al. Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis. PLoS Med 2011;8(7):e1001053.
[7] Siston AM, Rasmussen SA, Honein MA, Fry AM, Seib K, Callaghan WM, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 2010;303(15):1517–25.
[8] Centers for Disease Control and Prevention (CDC). Maternal and infant outcomes among severely ill pregnant and postpartum women with 2009 pandemic influenza A (H1N1)—United States, April 2009–August 2010. MMWR Morb Mortal Wkly Rep 2011;60(35):1193–6.
[9] Memoli MJ, Harvey H, Morens DM, Taubenberger JK. Influenza in pregnancy. Influenza Other Respi Viruses 2013;7(6):1033–9.
3. Immunobiological aspects of vaccines in pregnancy: Maternal perspective

I. Concepts of maternal immunization

[10] Katz MA, Gessner BD, Johnson J, Skidmore B, Knight M, Bhat N, et al. Incidence of influenza virus infection among pregnant women: a systematic review. BMC Pregnancy Childbirth 2017;17(1):155.

[11] Kay AW, Fukuyama J, Aziz N, Dekker CL, Mackey S, Swan GE, et al. Enhanced natural killer-cell and T-cell responses to influenza A virus during pregnancy. Proc Natl Acad Sci U S A 2014;111(40):14506–11.

[12] Engels G, Hierweger AM, Hoffmann J, Thieme R, Thiele S, Bertram S, et al. Pregnancy-related immune adaptation promotes the emergence of highly virulent H1N1 influenza virus strains in allogenically pregnant mice. Cell Host Microbe 2017;21(3):321–33.

[13] Le Gars M, Kay AW, Bayless NL, Aziz N, Dekker CL, Swan GE, et al. Increased proinflammatory responses of monocytes and plasmacytoid dendritic cells to influenza A virus infection during pregnancy. J Infect Dis 2016;214(11):1666–71.

[14] Steinhoff MC, Katz J, Englund JA, Khatri SK, Shrestha L, Kuypers J, et al. Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial. Lancet Infect Dis 2017;17(9):981–9.

[15] Tapia MD, Sow SO, Tamboura B, Tégueté I, Pasetti MF, Kodio M, et al. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. Lancet Infect Dis 2016;16(9):1026–35.

[16] Madhi SA, Cutland CL, Kuwanda L, Weinberg A, Hugo A, Jones S, et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014;371(10):918–31.

[17] Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359(15):1555–64.

[18] Datta S, Walsh EE, Peterson DR, Falsy AR. Can analysis of routine viral testing provide accurate estimates of respiratory syncytial virus disease burden in adults? J Infect Dis 2017;215(11):1706–10.

[19] Chu HY, Katz J, Tielsch J, Khatri SK, Shrestha L, LeClerq SC, et al. Clinical presentation and birth outcomes associated with respiratory syncytial virus infection in pregnancy. PLoS One 2016;11(3):e0152015.

[20] Madhi SA, Cutland CL, Downs S, Jones S, van Niekerk N, Simoes EAF, et al. Burden of respiratory syncytial virus infection in South African human immunodeficiency virus (HIV)-infected and HIV-uninfected pregnant and postpartum women: a longitudinal cohort study. Clin Infect Dis 2018;66(11):1658–65.

[21] Lenahan JL, Englund JA, Katz J, Kuypers J, Wald A, Magaret A, et al. Human metapneumovirus and other respiratory viral infections during pregnancy and birth, Nepal. Emerg Infect Dis 2017;23(8).

[22] Philpott EK, Englund JA, Katz J, Tielsch J, Khatri S, LeClerq SC, et al. Febrile rhinovirus illness during pregnancy is associated with low birth weight in Nepal. Open Forum Infect Dis 2017;4(2):ofx073.

[23] Assiri A, Abedi GR, Al Masri M, Bin Saeed A, Gerber SI, Watson JT. Middle east respiratory syndrome coronavirus infection during pregnancy: a report of 5 cases from Saudi Arabia. Clin Infect Dis 2016;63(7):951–3.

[24] Pilorgé L, Chartier M, Méritet J-F, Cervantes M, Tsatsaris V, Launay O, et al. Rhinoviruses as an underestimated cause of influenza-like illness in pregnancy during the 2009–2010 influenza pandemic. J Med Virol 2013;85(8):1473–7.

[25] Esmonde TF, Herdman G, Anderson G. Chickenpox pneumonia: an association with pregnancy. Thorax 1989;44(10):812–5.

[26] Triebwasser JH, Harris RE, Bryant RE, Rhoades ER. Varicella pneumonia in adults. Report of seven cases and a review of literature. Medicine (Baltimore) 1967;46(5):409–23.

[27] Faryani SG, Arvin AM. Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med 1986;314(24):1542–6.
I. Concepts of maternal immunization

References

[28] Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. Am J Med 1981;70(2):252–5.

[29] Pérez-Gracia MT, Suay-García B, Mateos-Lindemann ML. Hepatitis E and pregnancy: current state. Rev Med Virol 2017;27(3):e1929. https://doi.org/10.1002/rmv.1929.

[30] Yang C, Yu W, Bi Y, Long F, Li Y, Wei D, et al. Increased oestradiol in hepatitis E virus-infected pregnant women promotes viral replication. J Viral Hepat 2018;25(6):742–51.

[31] Lamont RF, Sobel J, Mazaki-Tovi S, Kusanovic JP, Vaisbuch E, Kim SK, et al. Listeriosis in human pregnancy: a systematic review. J Perinat Med 2011;39(3):227–36.

[32] McLauchlin J. Human listeriosis in Britain, 1967-85, a summary of 722 cases. 1. Listeriosis during pregnancy and in the newborn. Epidemiol Infect 1990;104(2):181–9.

[33] Robbins JR, Skrzypczynska KM, Zeldovich VB, Kapidzic M, Bakardjiev AI. Placental syncytiotrophoblast constitutes a major barrier to vertical transmission of Listeria monocytogenes. PLoS Pathog 2010;6(1):e1000732.

[34] Bakardjiev AI, Theriot JA, Portnoy DA. Listeria monocytogenes traffic from maternal organs to the placenta and back. PLoS Pathog 2006;2(6):e66.

[35] Luxemburger C, Ricci F, Nosten F, Raimond D, Bathet S, White NJ. The epidemiology of severe malaria in an area of low transmission in Thailand. Trans R Soc Trop Med Hyg 1997;91(3):256–62.

[36] Ataide R, Mayor A, Rogerson SJ. Malaria, primigravidae, and antibodies: knowledge gained and future perspectives. Trends Parasitol 2014;30(2):85–94.

[37] Radeva-Petrova D, Kayentao K, ter Kuile FO, Sinclair D, Garner P. Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment. Cochrane Database Syst Rev 2014;10:CD000169.

[38] McGready R, Lee SJ, Wiladphaingern J, Ashley EA, Rijken MJ, Boel M, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis 2012;12(5):388–96.

[39] Kurtis JD, Raj DK, Michełow IC, Park S, Nixon CE, McDonald EA, Nixon CP, Pond-Tor S, Jha A, Taliano RJ, Kabyemela ER, Friedman JF, Duffy PE, Fried M. Maternally-derived antibodies to Schizont Egress Antigen-1 and protection of infants from severe malaria. Clin Infect Dis 2019;68(10):1718–24. https://doi.org/10.1093/cid/ciy728. PMID: 30165569.

[40] Vynnycky E, Papadopoulos T, Angelis K. The impact of measles-rubella vaccination on the morbidity and mortality from congenital rubella syndrome in 92 countries. Hum Vaccin Immunother 2019;15(2):309–16.

[41] Corely L, Wald A. Maternal and neonatal herpes simplex virus infections. N Engl J Med 2009;361(14):1376–85.

[42] Roth K, Ferreira VH, Kaushic C. HSV-2 vaccine: current state and insights into development of a vaccine that targets genital mucosal protection. Microb Pathog 2013;58:45–54.

[43] Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, et al. Efficacy results of a trial of a herpes simplex vaccine. N Engl J Med 2012;366(1):34–43.

[44] Patel CD, Backes IM, Taylor SA, Jiang Y, Marchant A, Pesola JM, et al. Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity. Sci Transl Med 2019;11(487).

[45] Adler SP, Nigro G. Prevention of maternal-fetal transmission of cytomegalovirus. Clin Infect Dis 2013;57(Suppl 4):S189–92.

[46] Ross SA, Arora N, Novak Z, Fowler KB, Britt WJ, Boppana SB. Cytomegalovirus re-infections in healthy seroimmune women. J Infect Dis 2010;201(3):386–9.

[47] Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang M-L, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009;360(12):1191–9.

[48] Plotkin SA, Boppana SB. Vaccination against the human cytomegalovirus. Vaccine 2018; https://doi.org/10.1016/j.vaccine.2018.02.089. (e-pub ahead of print). PMID: 29622379.
Immunobiological aspects of vaccines in pregnancy: Maternal perspective

I. Concepts of maternal immunization

[49] Driggers RW, Ho C-Y, Korhonen EM, Kuivanen S, Jääskeläinen AJ, Smura T, et al. Zika virus infection with prolonged maternal viremia and fetal brain abnormalities. N Engl J Med 2016;374(22):2142–51.

[50] Suy A, Sulleiro E, Rodó C, Vázquez É, Bocanegra C, Molina I, et al. Prolonged Zika virus viremia during pregnancy. N Engl J Med 2016;375(26):2611–3.

[51] Oduyebo T, Polen KD, Walke HT, Reagan-Steiner S, Lathrop E, Rabe IB, et al. Update: interim guidance for health care providers caring for pregnant women with possible Zika virus exposure—United States (including U.S. territories), July 2017. MMWR Morb Mortal Wkly Rep 2017;66(29):781–93.

[52] Brasil P, Pereira JP, Moreira ME, Ribeiro Nogueira RM, Damasceno L, Wakimoto M, et al. Zika virus infection in pregnant women in Rio de Janeiro. N Engl J Med 2016;375(24):2321–34.

[53] Aghaeepour N, Ganio EA, Mcilwain D, Tsai AS, Tingle M, Van Gassen S, et al. An immune clock of human pregnancy. Sci Immunol 2017;2(15).

[54] Mahmoud F, Abul H, Omu A, Al-Rayses S, Haines D, Whaley K. Pregnancy-associated changes in peripheral blood lymphocyte subpopulations in normal Kuwaiti women. Gynecol Obstet Invest 2001;52(4):232–6.

[55] Watanabe M, Iwatani Y, Kaneda T, Hidaka Y, Mitsuda N, Morimoto Y, et al. Changes in T, B, and NK lymphocyte subsets during and after normal pregnancy. Am J Reprod Immunol 1997;37(5):368–77.

[56] Zimmer JP, Garza C, Butte NF, Goldman AS. Maternal blood B-cell (CD19+) percentages and serum immunoglobulin concentrations correlate with breast-feeding behavior and serum prolactin concentration. Am J Reprod Immunol 1998;40(1):57–62.

[57] Matthiesen L, Berg G, Ernerudh J, Håkansson L. Lymphocyte subsets and mitogen stimulation of blood lymphocytes in normal pregnancy. Am J Reprod Immunol 1996;35(2):70–9.

[58] Valdimarsson H, Mulholland C, Fridriksdottir V, Coleman DV. A longitudinal study of leucocyte blood counts and lymphocyte responses in pregnancy: a marked early increase of monocyte-lymphocyte ratio. Clin Exp Immunol 1983;53(2):437–43.

[59] Moore MP, Carter NP, Redman CW. Lymphocyte subsets defined by monoclonal antibodies in human pregnancy. Am J Reprod Immunol 1983;3(4):161–4.

[60] Kincade PW, Medina KL, Smithson G, Scott DC. Pregnancy: a clue to normal regulation of B lymphopoiesis. Immunol Today 1994;15(11):539–44.

[61] Kanda N, Tamaki K. Estrogen enhances immunoglobulin production by human PBMCs. J Allergy Clin Immunol 1999;103(2 Pt 1):282–8.

[62] Correale J, Farez MF, Ysraelit MC. Role of prolactin in B cell regulation in multiple sclerosis. J Neuroimmunol 2014;269(1–2):76–86.

[63] McGregor IA, Rowe DS, Wilson ME, Billevicz WZ. Plasma immunoglobulin concentrations in an African (Gambian) community in relation to season, malaria and other infections and pregnancy. Clin Exp Immunol 1970;7(1):51–74.

[64] Amino N, Tanizawa O, Miyai K, Tanaka F, Hayashi C, Kawashima M, et al. Changes of serum immunoglobulins IgG, IgA, IgM, and IgE during pregnancy. Obstet Gynecol 1978;52(4):415–20.

[65] Rowe DS, McGregor IA, Smith SJ, Hall P, Williams K. Plasma immunoglobulin concentrations in a West African (Gambian) community and in a group of healthy British adults. Clin Exp Immunol 1968;3(1):63–79.

[66] Logie DE, McGregor IA, Rowe DS, Billevicz WZ. Plasma immunoglobulin concentrations in mothers and newborn children with special reference to placental malaria: studies in the Gambia, Nigeria, and Switzerland. Bull World Health Organ 1973;49(6):547–54.

[67] Zeng Z, Surewaard BGJ, Wong CHY, Guettler C, Petri B, Burkhard R, et al. Sex-hormone-driven innate antibodies protect females and infants against EPEC infection. Nat Immunol 2018;19(10):1100–11.
I. Concepts of maternal immunization

References

[68] Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014;5:520.

[69] Jernwein MF, Alter G. The immunoregulatory roles of antibody glycosylation. Trends Immunol 2017;38(5):358–72.

[70] Bondt A, Rombouts Y, Selman MHJ, Hensbergen PJ, Reiding KR, Hazes JMW, et al. Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes. Mol Cell Proteomics 2014;13(11):3029–39.

[71] Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM, et al. Decoding the human immunoglobulin G-glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated-effector activities. Front Immunol 2017;8:877.

[72] Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006;313(5787):670–3.

[73] Bondt A, Selman MHJ, Deelder AM, Hazes JMW, Willemse SP, Wuhrer M, et al. Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. J Proteome Res 2013;12(10):4522–31.

[74] Pauklin S, Sernández JV, Bachmann G, Ramiro AR, Petersen-Mahrt SK. Estrogen directly activates AID transcription and function. J Exp Med 2009;206(1):99–111.

[75] Della Bella S, Giannelli S, Cozzi V, Signorelli V, Cappelletti M, Cetin I, et al. Incomplete activation of peripheral blood dendritic cells during healthy human pregnancy. Clin Exp Immunol 2011;164(2):180–92.

[76] Yoshimura T, Inaba M, Sugiuara K, Nakajima T, Ito T, Nakamura K, et al. Analyses of dendritic cell subsets in pregnancy. Am J Reprod Immunol 2003;50(2):137–45.

[77] Shin S, Jang JY, Roh EY, Yoon JH, Kim JS, Han KS, et al. Differences in circulating dendritic cell subtypes in pregnant women, cord blood and healthy adult women. J Korean Med Sci 2009;24(5):853–9.

[78] Ueda Y, Hagihara M, Okamoto A, Higuchi A, Tanabe H, Hirabayashi K, et al. Frequencies of dendritic cells (myeloid DC and plasmacytoid DC) and their ratio reduced in pregnant women: comparison with umbilical cord blood and normal healthy adults. Hum Immunol 2003;64(12):1144–51.

[79] Young BC, Stanic AK, Panda B, Rueda BR, Panda A. Longitudinal expression of Toll-like receptors on dendritic cells in uncomplicated pregnancy and postpartum. Am J Obstet Gynecol 2014;210(5):445.e1–6.

[80] Nuriel-Ohayon M, Neuman H, Koren O. Microbial changes during pregnancy, birth, and infancy. Front Microbiol 2016;7:1031.

[81] Koren O, Goodrich JK, Cullender TC, Spor A, Laitinen K, Bäckhed HK, et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell 2012;150(3):470–80.

[82] Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect Dis 2010;10(5):338–49.

[83] Hulka JF. Effectiveness of polyvalent influenza vaccine in pregnancy. Report of a controlled study during an outbreak of Asian influenza. Obstet Gynecol 1964;23:830–7.

[84] Murray DL, Imagawa DT, Okada DM, St Geme JW. Antibody response to monovalent A/New Jersey/8/76 influenza vaccine in pregnant women. J Clin Microbiol 1979;10(2):184–7.

[85] Christian LM, Porter K, Karlsson E, Schultz-Cherry S, Iams JD. Serum proinflammatory cytokine responses to influenza virus vaccine among women during pregnancy versus non-pregnancy. Am J Reprod Immunol 2013;70(1):45–53.

[86] Kay AW, Bayless NL, Fukuyama J, Aziz N, Dekker CL, Mackey S, et al. Pregnancy does not attenuate the antibody or plasmablast response to inactivated influenza vaccine. J Infect Dis 2015;212(6):861–70.
Immunobiological aspects of vaccines in pregnancy: Maternal perspective

I. Concepts of maternal immunization

[87] Schlaudecker EP, McNeal MM, Dodd CN, Ranz JB, Steinhoff MC. Pregnancy modifies the antibody response to trivalent influenza immunization. J Infect Dis 2012;206(11):1670–3.

[88] Bischoff AL, Følsgaard NV, Carson CG, Stokholm J, Pedersen L, Holmberg M, et al. Altered response to A(H1N1)pnd09 vaccination in pregnant women: a single blinded randomized controlled trial. PLoS One 2013;8(4):e56700.

[89] Schlaudecker EP, Ambroggio L, McNeal MM, Finkelman FD, Way SS. Declining responsiveness to influenza vaccination with progression of human pregnancy. Vaccine 2018;36(31):4734–41.

[90] Ohfuji S, Fukushima W, Deguchi M, Kawabata K, Yoshida H, Hatayama H, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine among pregnant women: lowered antibody response by prior seasonal vaccination. J Infect Dis 2011;203(9):1301–8.

[91] Munoz FM, Bond NH, Maccato M, Pinell P, Hammill HA, Swamy GK, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 2014;311(17):1760–9.

[92] Huygen K, Caboré RN, Maertens K, Van Damme P, Leuridan E. Humoral and cell mediated immune responses to a pertussis containing vaccine in pregnant and non-pregnant women. Vaccine 2015;33(33):4117–23.

[93] Fortner KB, Swamy GK, Broder KR, Jimenez-Truque N, Zhu Y, Moro PL, et al. Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women. Vaccine 2018;36(42):6354–60.

[94] Tsang JS. Utilizing population variation, vaccination, and systems biology to study human immunology. Trends Immunol 2015;36(8):479–93.

[95] Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis 2013;56(4):539–44.

[96] Abu Raya B, Edwards KM, Scheifele DW, Halperin SA. Pertussis and influenza immunisation during pregnancy: a landscape review. Lancet Infect Dis 2017;17(7):e209–22.

[97] Abu Raya B, Bamberger E, Almog M, Peri R, Srugo I, Kessel A. Immunization of pregnant women against pertussis: the effect of timing on antibody avidity. Vaccine 2015;33(16):1948–52.

[98] Heyderman RS, Madhi SA, French N, Cutland C, Ngwira B, Kayambo D, et al. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial. Lancet Infect Dis 2016;16(5):546–55.

[99] Weinberg A, Muresan P, Richardson KM, Fenton T, Dominguez T, Bloom A, et al. Determinants of vaccine immunogenicity in HIV-infected pregnant women: analysis of B and T cell responses to pandemic H1N1 monovalent vaccine. PLoS One 2015;10(4):e0122431.

[100] Koch MA, Reiner GL, Lugo KA, Kreuk LSM, Stanbery AG, Ansaldo E, et al. Maternal IgG and IgA antibodies dampen mucosal T helper cell responses in early life. Cell 2016;165(4):827–41.

[101] Gomez de Agüero M, Ganal-Vonarburg SC, Fuhrer T, Rupp S, Uchimura Y, Li H, et al. The maternal microbiota drives early postnatal innate immune development. Science 2016;351(6279):1296–302.

[102] Ohsaki A, Venturelli N, Buccigrosso TM, Osganian SK, Lee J, Blumberg RS, et al. Maternal IgG immune complexes induce food allergen-specific tolerance in offspring. J Exp Med 2018;215(1):91–113.

[103] Roopenian DC, Akiles S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7(9):715–25.
I. Concepts of maternal immunization

References

[104] Bundhoo A, Paveglio S, Rafti E, Dhongade A, Blumberg RS, Matson AP. Evidence that FcRn mediates the transplacental passage of maternal IgE in the form of IgG anti-IgE/IgE immune complexes. Clin Exp Allergy 2015;45(6):1085–98.

[105] Linder N, Ohel G. In utero vaccination. Clin Perinatol 1994;21(3):663–74.

[106] Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012;2012:985646.

[107] van den Berg JP, Westerbeek EA, van der Klis FR, Berbers GA, van Elburg RM. Transplacental transport of IgG antibodies to preterm infants: a review of the literature. Early Hum Dev 2011;87(2):67–72.

[108] Einarsdottir HK, Selman MHJ, Kapur R, Scherjon S, Koeleman CAM, Deelder AM, et al. Comparison of the Fc glycosylation of fetal and maternal immunoglobulin G. Glycoconj J 2013;30(2):147–57.

[109] Jansen BC, Bondt A, Reiding KR, Scherjon SA, Vidarsson G, Wuhrer M. MALDITOF-MS reveals differential N-linked plasma- and IgG-glycosylation profiles between mothers and their newborns. Sci Rep 2016;6:34001.

[110] Ishikawa T, Takizawa T, Iwaki J, Mishima T, Ui-Tei K, Takeshita T, et al. Fc gamma receptor IIb participates in maternal IgG trafficking of human placental endothelial cells. Int J Mol Med 2015;35(5):1273–89.

[111] Jennewein MF, Abu-Raya B, Jiang Y, Alter G, Marchant A. Transfer of maternal immunity and programming of the newborn immune system. Semin Immunopathol 2017;39(6):605–13.

[112] Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, et al. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep 2018;67(2):1–44.

[113] Eberhardt CS, Blanchard-Rohner G, Lemaitre B, Boukrid M, Combescure C, Othenin-Girard V, et al. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. Clin Infect Dis 2016;62(7):829–36.

[114] Amirthalingam G, Andrews N, Campbell H, Ribeiro S, Kara E, Donegan K, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet Lond Engl 2014;384(9953):1521–8.

[115] Katz J, Englund JA, Steinhoff MC, Katry SK, Shrestha L, Kuyipers J, et al. Impact of timing of influenza vaccination in pregnancy on transplacental antibody transfer, influenza incidence, and birth outcomes: a randomized trial in rural Nepal. Clin Infect Dis 2018;67(3):334–40.

[116] Englund JA, Glezen WP, Turner C, Harvey J, Thompson C, Siber GR. Transplacental antibody transfer following maternal immunization with polysaccharide and conjugate Haemophilus influenzae type b vaccines. J Infect Dis 1995;171(1):99–105.

[117] de Moraes-Pinto MI, Verhoeff F, Chimsuku L, Milligan PJ, Wesumperuma L, Broadhead RL, et al. Placental antibody transfer: influence of maternal HIV infection and placental malaria. Arch Dis Child Fetal Neonatal Ed 1998;79(3):F202–5.

[118] Dauby N, Goetghebuer T, Kollmann TR, Levy J, Marchant A. Uninfected but not unaffected: chronic maternal infections during pregnancy, fetal immunity, and susceptibility to postnatal infections. Lancet Infect Dis 2012;12(4):330–40.

[119] Abu-Rayab R, Smolen KK, Willems F, Kollmann TR, Marchant A. Transfer of maternal antimicrobial immunity to HIV-exposed uninfected newborns. Front Immunol 2016;7:338.

[120] Evans C, Jones CE, Prendergast AJ. HIV-exposed, uninfected infants: new global challenges in the era of paediatric HIV elimination. Lancet Infect Dis 2016;16(6):e92–107.
I. Concepts of maternal immunization

1. **Okoko BJ, Wesumperuma LH, Ota MO, Pinder M, Banya W, Gomez SF, et al.** The influence of placental malaria infection and maternal hypergammaglobulinemia on transplacental transfer of antibodies and IgG subclasses in a rural west African population. J Infect Dis 2001;184(3):627–32.

2. **Brair ME, Brabin BJ, Milligan P, Maxwell S, Hart CA.** Reduced transfer of tetanus antibodies with placental malaria. Lancet Lond Engl 1994;343(8891):208–9.

3. **Cumberland P, Shulman CE, Maple PAC, Bulmer JN, Dorman EK, Kauwondo K, et al.** Maternal HIV infection and placental malaria reduce transplacental antibody transfer and tetanus antibody levels in newborns in Kenya. J Infect Dis 2007;196(4):550–7.

4. **Ogolla S, Daud II, Asito AS, Sumba OP, Ouma C, Vulule J, et al.** Reduced transplacental transfer of a subset of Epstein-Barr virus-specific antibodies to neonates of mothers infected with Plasmodium falciparum malaria during pregnancy. Clin Vaccine Immunol 2015;22(11):1197–205.

5. **Atwell JE, Thumar B, Robinson LJ, Tobby R, Yambo P, Ome-Kaïus M, et al.** Impact of placental malaria and hypergammaglobulinemia on transplacental transfer of respiratory syncytial virus antibody in Papua New Guinea. J Infect Dis 2016;213(3):423–31.

6. **Jones CE, Naidoo S, De Beer C, Esser M, Kampmann B, Hesselink AC.** Maternal HIV infection and antibody responses against vaccine-preventable diseases in uninfected infants. JAMA 2011;305(6):576–84.

7. **Goetghheuer T, Smolen KK, Adler C, Das J, McBride T, Smits G, Lecomte S, Haelterman E, Barlow P, Piedra PA, van der Klis F, Kollmann TR, Lauffenburger DA, Alter G, Levy J, Marchant A.** Initiation of antiretroviral therapy before pregnancy reduces the risk of infection-related hospitalization in human immunodeficiency virus-exposed uninfected infants born in a high-income country. Clin Infect Dis 68 (7), 1193–1203. https://doi.org/10.1093/cid/ciy673. PMID: 30215689.

8. **Ruck C, Reikie BA, Marchant A, Kollmann TR, Kakkar F.** Linking susceptibility to infectious diseases to immune system abnormalities among HIV-exposed uninfected infants. Front Immunol 2016;7:310.

9. **Abzug MJ, Nachman SA, Muresan P, Handelsman E, Watts DH, Fenton T, et al.** Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women. Clin Infect Dis 2013;56(10):1488–97.

10. **Victora CG, Bahl R, Barros AJD, França GVA, Horton S, Krasevec J, et al.** Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. Lancet Lond Engl 2016;387(10017):475–90.

11. **Sankar MJ, Sinha B, Chowdhury R, Bhandari N, Taneja S, Martines J, et al.** Optimal breastfeeding practices and infant and child mortality: a systematic review and meta-analysis. Acta Paediatr 2015;104(467):3–13.

12. **Johansen FE, Braathen R, Brandtzaeg P.** The J chain is essential for polymeric Ig receptor-mediated epithelial localization in IgA. J Immunol 2001;167(9):5185–92.

13. **Hocini H, Bomsel M.** Infectious human immunodeficiency virus can rapidly penetrate a tight human epithelial barrier by transcytosis in a process impaired by mucosal immunoglobulins. J Infect Dis 1999;179(Suppl 3):S448–53.

14. **Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J.** HIV-specific antibodies capable of ADCC are common in breastfeeding and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 2012;8(6):e1002739.

15. **Mazur NI, Horsley NM, Englund JA, Nederend M, Magaret A, Kumar A, Jacobino SR, de Haan CAM, Khatry SK, LeClerq SC, Steinhoff MC, Tielsch JM, Katz J, Graham BS, Bont LJ, Leusen JHW, Chu HY.** Breastmilk prefusion F immunoglobulin G as a correlate of protection against respiratory syncytial virus acute respiratory illness. J Infect Dis 2019;219(1):59–67. https://doi.org/10.1093/infdis/jiy477. PMID: 30107412; PMCID: PMC6284547.

I. Concepts of maternal immunization
I. Concepts of maternal immunization

[136] Shao H-Y, Chen Y-C, Chung N-H, Lu Y-J, Chang C-K, Yu S-L, et al. Maternal immunization with a recombinant adenovirus-expressing fusion protein protects neonatal cotton rats from respiratory syncytia virus infection by transferring antibodies via breastmilk and placenta. Virology 2018;521:181–9.

[137] Caballero-Flores G, Sakamoto K, Zeng MY, Wang Y, Hakim J, Matus-Acuña V, et al. Maternal immunization confers protection to the offspring against an attaching and effacing pathogen through delivery of IgG in breastmilk. Cell Host Microbe 2019;25(2):313–323.e4.